SUZHOU, China, April 19, 2021 /PRNewswire/ -- On April 16, 2021, Suzhou Porton Biologics Ltd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO service, officially announced the closing of Series A funding round, which raised 400 million RMB. The participants of the financing include industry's top-tier investment institutions, SDIC and GL Ventures, HM Capital, Huashan Ruilian and Momentum Venture.
Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID) worth $4.5 million to take its intranasal anthrax vaccine into Phase 1 clinical trials.